Is delayed three-month re-excision safe for patients who have undergone unplanned excision of soft tissue sarcomas? Authors: Jin Tao, Zhuoyu Li, Li Yuan, Xu Hairong, Hao Lin, Niu Xiaohui, Weifeng Liu Published: 2026 ABSTRACT BackgroundThe optimal timing for systematic re-excision following the unplanned excision (UE) of soft tissue sarcomas (STS) remains controversial. This study evaluated the impact of delayed versus immediate re-excision on overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS).Methods We retrospectively analysed patients who underwent re-excision for primary STS following UE between August 2011 and February 2019. Patients with metastasis at presentation or a follow-up of less than two years were excluded. The cohort was stratified into an early re-excision (RE) group (≤ 3 months from initial UE) and a late RE group (> 3 months). The LRFS, PFS, OS, and the extent of excision were assessed.ResultsA total of 104 patients met the inclusion criteria of this study, including 74 cases in the early RE group and 30 cases in the late RE group. At a mean follow-up of 61.0 ± 20.5 months, the 5-year OS was 86.5% and 88.1% in the early RE group and the late RE group, respectively (P=0.501). No significant differences were observed in 5-year LRFS (98.9% vs. 88.8%, P=0.168) or 5-year MRFS (88.6% vs. 81.9%, P=0.764). For a subset of 12 patients in the late RE group who underwent serial MRI, the median maximum edema diameter decreased significantly from 93.8 mm at the initial visit to 54.9 mm prior to delayed re-excision (P=0.001)ConclusionsDelayed re-excision beyond three months did not negatively impact recurrence or survival rates compared to immediate intervention. Furthermore, this delayed approach allows postoperative edema to subside, potentially reducing the required extent of resection and the subsequent need for complex flap reconstruction. Introduction Soft tissue sarcomas (STS) are relatively common in orthopedic oncology, and its incidence is 10 times higher than that of primary malignant bone tumors [1]. Standard management dictates a preoperative biopsy followed by a planned wide excision based on the definitive histological diagnosis. Depending on the tumor grade, adjuvant radiotherapy or chemotherapy may also be indicated. According to the literature, 10% of patients will have local recurrence after standard treatment, and 20–30% of patients will have distant metastases [2–6]. Wide excision is critical for minimising local recurrence; therefore, it is particularly important to do a planned excision at the initial presentation. However, many patients initially present to non-specialised institutions, frequently resulting in the unplanned excision (UE) of the sarcoma. Following UE, systematic re-excision (RE) reveals residual disease in approximately 50% of surgical specimens. Consequently, RE is widely accepted as necessary to eradicate potential residual tumor cells and secure adequate surgical margins. The area of re-excision should be evaluated based on the MRI after the previous excision, and the areas that may be contaminated by the operation should be completely removed. Previous studies have demonstrated that within 3 months postoperatively, the surgical site may develop edema, hematoma, and seroma, thereby exaggerating the necessary resection range [7, 8]. If surgery is performed during this phase, the resection field must be expanded to encompass these reactive changes. This enlarged surgical footprint proportionally increases the necessity for complex soft tissue coverage, such as free skin grafting or flap transfer, which can impede patient recovery and compromise limb function. We hypothesised that delaying RE until after the initial three-month inflammatory phase allows MRI to delineate the true tumor extent more accurately, thereby optimising the surgical plan. Therefore, we ask the following questions: (1) When is it appropriate to undergo re-excision? (2) Does delayed re-excision will have an adverse effect on local recurrence, metastasis and survival of the patients? (3) Can delayed re-excision reduce the incidence of flap or skin grafting? Methods This retrospective study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Beijing Jishuitan Hospital (No. J2025-013). Informed consent was exempted by the Ethics Committee of Beijing Jishuitan Hospital. Patients and methods The data were extracted from Jishuitan (JST) Bone and Soft Tissue Tumor database (http://www.sarcoma-jst.net/JST_Sarcoma/home.aspx) between August 2011 and February 2019. The inclusion criteria were defined as: (1) Patients with soft tissue sarcomas of the trunk and limb underwent unplanned excision in other hospitals, (2) The patients were all confirmed primary malignant soft tissue sarcoma by postoperative pathology in our hospital, (3) The cases were all performed with re-excision in our department. The exclusion criteria included: (1) Patients with planned excision biopsy or open biopsy in other hospitals; (2) Indeterminate malignant pathology; (3) Patients who have had tumor metastasis at the time of consultation in our department; (4) The follow-up time of patients was less than 2 years. A total of 104 patients met the inclusion criteria of this study, including 74 cases in early re-excision group and 30 cases in late re-excision group. The mean age was 43.8 ± 16.5 years (range, 8–80 years). The basic characteristics of the cases were shown in Table 1. Table 1Characteristics of all patientsTotal(n, %)Early RE group (n, %)Late REgroup(n, %) P Value1047430Gender0.106Male7154 (73%)17 (57%)Female3320 (27%)13 (43%)Age0.915Age ≥ 60 years2518 (24%)7 (23%)Age < 60 years7956 (76%)23 (77%)Location0.413Limb9166 (89%)25 (83%)Trunk138 (11%)5 (17%)Depth0.696Deep6245 (61%)17 (57%)Superfificial4229 (39%)13 (43%)Size0.914Size ≥ 50 mm3223 (31%)9 (30%)Size < 50 mm7251 (69%)21 (70%)Tumor grade0.338Grade 1137 (9%)6 (20%)Grade 22317 (23%)6 (20%)Grade 36850 (68%)18 (60%)Surgical margin0.718Wide3422 (30%)10 (33%)Marginal7552 (70%)20 (67%)Intralesional(73%)(73%)Interval time(median, range, days)58 (12–88)105 (90–189) Table 1Characteristics of all patientsTotal(n, %)Early RE group (n, %)Late REgroup(n, %) P Value1047430Gender0.106Male7154 (73%)17 (57%)Female3320 (27%)13 (43%)Age0.915Age ≥ 60 years2518 (24%)7 (23%)Age < 60 years7956 (76%)23 (77%)Location0.413Limb9166 (89%)25 (83%)Trunk138 (11%)5 (17%)Depth0.696Deep6245 (61%)17 (57%)Superfificial4229 (39%)13 (43%)Size0.914Size ≥ 50 mm3223 (31%)9 (30%)Size < 50 mm7251 (69%)21 (70%)Tumor grade0.338Grade 1137 (9%)6 (20%)Grade 22317 (23%)6 (20%)Grade 36850 (68%)18 (60%)Surgical margin0.718Wide3422 (30%)10 (33%)Marginal7552 (70%)20 (67%)Intralesional(73%)(73%)Interval time(median, range, days)58 (12–88)105 (90–189) Characteristics of all patients Interval time (median, range, days) In early re-excision group (interval from unplaned excision to re-resection < 3 months), undifferentiated pleomorphic sarcoma (UPS, 27%) and liposarcoma (27%) were the most common pathological diagnoses, followed by synovial sarcoma (12%). Other diagnoses included myxofibrosarcoma (5%), dermatofibrosarcoma protuberans (5%), and leiomyosarcoma (5%). The remaining 13 cases included malignant peripheral nerve sheath tumors (3%), spindle cell sarcomas (2%), Ewing sarcomas (2%), and other rare soft tissue sarcomas (7%). In late re-excision group (≥ 3 months), the most common diagnoses were synovial sarcoma (23%), malignant peripheral nerve sheath tumor (13%), dermatofibrosarcoma protuberans (13%), and UPS (13%). The late RE group also included myxoid liposarcoma (10%) and leiomyosarcoma (7%). The remaining 6 cases included various other rare soft tissue sarcomas, including angiosarcoma (3%) and rhabdomyosarcoma (3%). The baseline demographic and clinical characteristics of the patients are summarised in Table 1. There were no statistically significant differences between early RE group and late RE group regarding gender, age, tumor location, depth, size, or histological grade (P > 0.05). We used the RECIST 1.1 criteria to evaluate tumor size changes. Statistical analysis OS, LRFS and PFS were calculated using the Kaplan–Meier method. OS was calculated from the date of diagnosis until the death date, regardless of cause, or until the date of last follow-up. LRFS was calculated from the date of diagnosis until the date of LR or the date of last follow-up. PFS was calculated from the date of diagnosis until the date of metastasis diagnosis or the date of last follow-up. Continuous variables are reported as median or mean ± standard deviations (SD). The paired-sample t-test was used to compare the edema extent between two MRI scans. The chi-square test was employed to assess the differences between the superficial and deep fascial layers. Univariate and multivariable Cox proportional hazards regression models were used to identify factors associated with overall survival and local-recurrence free survival. Variables that demonstrated a potential association with the outcome in the univariate analysis (p < 0.10) and clinically established prognostic factors were subsequently included in the multivariable Cox regression model to identify independent prognostic factors. SPSS software (version 26 for Windows) was used for statistical analysis. The statistical significance level was set at P < 0.05. Results Pathological findings and residual disease Histopathological examination of the re-excision specimens confirmed the presence of residual tumor in 25 (24.0%) of the 104 patients. Stratification by surgical timing, residual macroscopic or microscopic disease was identified in 16 patients (22%) in early RE group and 9 patients (30%) in late RE group (p = 0.365). Survival analysis The 5-year OS of early RE group patients was 86.5% ± 9.1%, while the 5-year OS of late RE group patients was 88.1% ± 16.9% (p = 0.501, Fig. 1). There were no significant differences in local relapse-free survival (LRFS) or progression-free survival (PFS) between the two groups. The 5-year LRFS of the early RE group was 98.9% ± 2.9%, while the 5-year LRFS of the late RE group was 88.8% ± 16.6% (P = 0.168). Furthermore, the 5-year PFS of the early RE group was 88.6% ± 8.6%, compared to 81.9% ± 19.7% in the late RE group (P = 0.769). Fig. 1A The 5-year OS of early RE group patients was 86.5% ± 9.1%, while 5-year OS of late RE group was 88.1% ± 16.9% (p = 0.501). B The 5-year LRFS of the early RE group was 98.9% ± 2.9%, while the 5-year LRFS of the late RE group was 88.8% ± 16.6% (P = 0.168). C The 5-year MRFS of the early RE group was 88.6% ± 8.6%, compared to 81.9% ± 19.7% in the late RE group (P = 0.769) A The 5-year OS of early RE group patients was 86.5% ± 9.1%, while 5-year OS of late RE group was 88.1% ± 16.9% (p = 0.501). B The 5-year LRFS of the early RE group was 98.9% ± 2.9%, while the 5-year LRFS of the late RE group was 88.8% ± 16.6% (P = 0.168). C The 5-year MRFS of the early RE group was 88.6% ± 8.6%, compared to 81.9% ± 19.7% in the late RE group (P = 0.769) A total of 4 patients had local recurrence, including 2 patients in early RE group and 2 patients in late RE group. Two patients underwent excision and remained disease-free at the latest follow-up. One patient developed local recurrence with concurrent multiple metastases 17 months post-RE. Later, the patient received targeted therapy, the tumor was maintained SD for 4 months and progressed later, and then the patient received radiotherapy. The patient remained alive at the 46-month follow-up. The fourth patient experienced local recurrence at 16 months post-RE, declined further intervention, and demonstrated localised tumor progression without evident metastasis at 24 months. There were 12 cases with metastasis, one of which was with popliteal lymph node metastasis, and the patient underwent a transfemoral amputation and died of multiple metastases at 7 months after the third operation. Another patient transitioned to palliative care and died nine months later. Ten cases had lung metastases. Of these, one patient with a malignant peripheral nerve sheath tumor underwent pulmonary metastasectomy and remained disease-free 24 months postoperatively. Another patient with leiomyosarcoma developed pulmonary metastasis at 15 months; following a poor response to chemotherapy, the patient received apatinib (achieving SD for 14 months), followed by metastasectomy and radiotherapy, and was alive one year post-thoracic surgery. The other eight patients with pulmonary metastases died secondary to disease progression. Surgical extent and soft tissue reconstruction There were 12 patients in late RE group have two MRIs, at their first visit of our department and before the re-excision, interval between two MRI scans ranged from 2 to 6 months. We measured the edema area shown on the two MRI, the mean maximum edema diameter decreased significantly from 93.8 ± 39.9 mm on the initial MRI to 54.9 ± 29.8 mm on the pre-re-excision MRI (P = 0.001, Table 2). In the entire cohort, 57 patients (54.8%) required soft tissue reconstruction, including flap transposition or skin grafting, following re-excision (Fig. 2). Consistent with the significant reduction in the mean maximum edema diameter observed on MRI, delayed surgery significantly decreased the surgical reconstructive burden. In early RE group, 46 patients (62%) required flap reconstruction or extensive skin grafting to achieve wound closure. In contrast, only 11 patients (36%) in late RE group required such procedures. This reduction in the frequency of complex soft tissue reconstruction in the delayed cohort was statistically significant (P = 0.031). Table 2Maximum edema diameter (MED) on two MRICaseMED on MRI T1WI (mm)MED on MRI T2WI (mm)P value1733622910318412146230584466101074120858209323210157421119012012206172Median93.8 ± 39.954.9 ± 29.80.001 Table 2Maximum edema diameter (MED) on two MRICaseMED on MRI T1WI (mm)MED on MRI T2WI (mm)P value1733622910318412146230584466101074120858209323210157421119012012206172Median93.8 ± 39.954.9 ± 29.80.001 Maximum edema diameter (MED) on two MRI Fig. 2A 65-year-old male patient with left thigh smooth muscle sarcoma underwent unplanned resection at another hospital. A Nine days postoperatively, extensive edema was observed at the resection site with a maximum diameter of 157 mm. B Three months postoperatively, the original resection site edema had reduced to 42 mm A 65-year-old male patient with left thigh smooth muscle sarcoma underwent unplanned resection at another hospital. A Nine days postoperatively, extensive edema was observed at the resection site with a maximum diameter of 157 mm. B Three months postoperatively, the original resection site edema had reduced to 42 mm Multivariate survival analysis Factors including patient age, tumor depth, tumor size (≥ 5 cm vs. <5 cm), histological grade, and the timing of re-excision were included in a multivariate Cox proportional hazards regression model (Table 3). After controlling for these covariates, high histological grade (HR, 3.62; 95% CI, 1.65–8.26; P = 0.008) and deep tumor location (HR, 1.59; 95% CI, 1.04–3.22; P = 0.034) remained independent predictors for worse overall survival. Delayed re-excision was not identified as an independent risk factor for decreased overall survival (HR, 1.12; 95% CI, 0.84–1.52; P = 0.216). Table 3Univariate and multivariable Cox regression analysisVariableCategoryUnivariate Cox modelMultivariate Cox modelHR95% CIp ValueHR95% CIp ValuePatient age≥ 60 yr1.090.75–1.590.6591.050.85–1.360.844< 60 yrReferenceReferenceTumor size≥ 5 cm1.350.89–1.780.1361.240.92–1.570.331< 5 cmReferenceReferenceTumor depthDeep1.881.08–5.160.0121.591.04–3.220.034SuperficialReferenceReferenceHistological gradeHigh4.232.56–13.40.0023.621.65–8.260.008Low / IntermediateReferenceReferenceTiming of Re-excisionDelayed1.120.84–1.520.2161.080.88–1.320.355Early / ImmediateReferenceReferenceSurgical marginAdequate0.890.65–1.230.3560.920.72–1.150.489InadequateReferenceReferenceAdjuvant radiotherapyNo0.930.84–1.090.4690.950.90–1.080.786YesReferenceReferenceDelayedre-excisionNo1.160.90–1.640.1581.120.84–1.520.216YesReferenceReference Table 3Univariate and multivariable Cox regression analysisVariableCategoryUnivariate Cox modelMultivariate Cox modelHR95% CIp ValueHR95% CIp ValuePatient age≥ 60 yr1.090.75–1.590.6591.050.85–1.360.844< 60 yrReferenceReferenceTumor size≥ 5 cm1.350.89–1.780.1361.240.92–1.570.331< 5 cmReferenceReferenceTumor depthDeep1.881.08–5.160.0121.591.04–3.220.034SuperficialReferenceReferenceHistological gradeHigh4.232.56–13.40.0023.621.65–8.260.008Low / IntermediateReferenceReferenceTiming of Re-excisionDelayed1.120.84–1.520.2161.080.88–1.320.355Early / ImmediateReferenceReferenceSurgical marginAdequate0.890.65–1.230.3560.920.72–1.150.489InadequateReferenceReferenceAdjuvant radiotherapyNo0.930.84–1.090.4690.950.90–1.080.786YesReferenceReferenceDelayedre-excisionNo1.160.90–1.640.1581.120.84–1.520.216YesReferenceReference Univariate and multivariable Cox regression analysis Delayed re-excision Discussion Our findings demonstrate that delaying re-excision for more than three months following the unplanned excision does not affect the local recurrence rate, distant metastasis rate, or overall survival of patients. Unplanned resection may lead to edema in normal soft tissues, resulting in excessive resection beyond actual needs. Compared with immediate blind re-resection, the delayed approach allows postoperative reactive changes to subside, facilitating a more precise surgical plan that significantly reduces the required resection area and the subsequent need for complex soft tissue reconstruction. The optimal timing of re-excision, early postoperative MRI is often confounded by a mixture of tumor, bleeding, and reactive edema signals. If excision is performed based on these early images, uncontaminated edematous normal soft tissue is frequently resected, unnecessarily enlarging the surgical footprint. By waiting for more than 2–3 months, the signal intensity of reactive edema gradually decreases, whereas the signal of residual tumor or true contamination does not. In our cohort, for patients who underwent serial MRI, the median maximum edema diameter significantly decreased from 93.8 mm at the initial visit to 54.9 mm before delayed re-excision. This radiologically proven resolution of edema provides a solid rationale for the 3-month threshold, allowing surgeons to design a more precise resection area. Consequently, this delayed approach significantly decreased the surgical reconstructive burden, reducing the need for complex flap reconstruction or extensive skin grafting from 62% in the early RE group to 37% in the late RE group. It is very important for soft tissue sarcoma patients who underwent unplanned excision to receive further standardised treatment after the operation. It was reported that the tumor residual rate after unplanned excision was up-to 50% (24%–91%) [9–12]. The results of our study showed that there were 25 patients (24%) with positive pathology after the unplanned excision, which was consistent with the literature. For patients with imaging-visible residual tumors, it was necessary to receive re-operative excision, and there is a consensus of opinion on this issue. However, for patients without visible residual tumors, it is controversial whether to do re-excision immediately. Some scholars believe that extensive re-excision should be carried out as soon as possible after unplanned excision, in order to remove possible tumor residues as much as possible 11. In their view, this treatment can help to reduce the risk of local recurrence and distant metastasis as well. According to their research, residual tumor, even when invisible to the naked eye, will increase the risk of metastasis and affect survival rate [11, 12], delay of definitive surgery after unplanned excision of STS results in adverse clinical outcome by allowing remaining cancer cells to proliferate. However, some studies have shown that the local recurrence of patients has no correlation with distant metastasis rate or overall survival rate [9, 13–19]. Their research results showed that the factors that affected distant metastasis were tumor grade, size, depth, and whether to do adjuvant radiotherapy according to the univariate analysis. However, the results of multivariate analysis showed that it was the tumor grade and depth, rather than local treatment that affect distant metastasis. The results of the study by Decanter et al. showed that there was no significant difference of the 5-year overall survival rate and distant metastasis rate between the patients in the group who did not undergo operation immediately, closely followed up and received operations until recurrence appeared and in the immediate operation group [13]. However, patients in the former group included patients who could receive excision but didn’t undergo excision, and patients who chose to undergo radiotherapy because of the high recurrence rate after extensive excision. There were 63.8% of patients in this group. After 5 years of close monitoring and follow-up, no local recurrence was seen, and unnecessary extensive excision was avoided. The overall local recurrence rate was higher than that of the latter group. In our study, 24% patients who received extensive re-excision showed residual tumors existed. Moreover, up to now, there was no more evidence to show that the patients could wait to receive re-operation until the time of local recurrence. Therefore, we comprehensively consider that we can perform re-excision for soft tissue sarcoma patients who underwent unplanned excision, but the time of excision needs to be further studied. At present, there are more and more studies on delayed surgery. The previous view was that enlarged excision should be carried out as soon as possible. However, more recent studies have shown that it is possible to postpone the operation appropriately, or even perform the operation until the time of local recurrence. Han et al. showed that patients who underwent re-excision within one month after unplanned excision had no significant difference in survival rate and local recurrence compared with patients who underwent delayed surgery one month later [20]. Our research is consistent with it, and we have also done an analysis of distant metastasis, showing that the delayed surgery did not increase the patient’s remote metastasis rate. Therefore, we believe that for patients with unplanned excision of soft tissue sarcomas, especially for patients with poor wound healing or severe swelling and severe edema around the wound after the initial excision, the re-excision can be postponed to wait for the patient’s local condition improves, when the MRI signal is relatively clear and the edema of normal tissue subsides. This does not increase the risk of local recurrence, distant metastasis and death of the patient. The oncological safety of delaying re-excision for more than three months warrants further biological consideration. It is counterintuitive that leaving potential microscopic residual disease in situ does not invariably lead to rapid local progression or dissemination. We hypothesise that the initial unplanned excision, despite compromising the anatomical barriers, severely disrupts the local tumor microenvironment and vascular network. This surgical trauma induces a state of localised hypoxia and triggers a robust inflammatory cascade, leading to dense fibrotic encapsulation of the surgical bed. This fibrotic response may temporarily arrest the rapid proliferation of residual microscopic disease. However, this ‘wait-and-see’ approach is not universally applicable; it requires careful patient selection. Highly aggressive subtypes or overtly macroscopic residual tumors on immediate postoperative imaging may still necessitate prompt intervention to prevent explosive local progression. Compared with patients undergoing planned excision, patients with UE need soft tissue reconstruction more frequently, including flap transposition and simple skin grafts, after re-excision [2, 3, 12]. Our research showed that more than half of the patients (57/104) underwent soft tissue reconstruction and the proportion was quite high. Many patients may avoid soft tissue reconstruction or only need a smaller area of reconstruction if they received planned excision at the first time. Due to the impact of unplanned excision, the proportion and area of soft tissue reconstruction increased. The area of soft tissue reconstruction was related to the patients’ function. Therefore, on the premise of oncological safety, we hoped to minimize the area of re-excision and reduce unnecessary excision in order to reduce the area of soft tissue reconstruction. After unplanned excision, the following factors need to be considered when surgeons design extensive re-excision: (1) The original image of the patients. Many patients have no image before UE. (2) Patient’s operation record to assess the impact of the first operation. (3) Current imaging examination to assess the current oncological situation. Of these three factors, the most valuable reference for the range of excision was the current image, but the assessment was also difficult. It had been reported that the accuracy rate of assessing whether there was tumor residue based on MRI was only 67.2%10. Due to the influence of the operation, tumor signals, bleeding signals and edema signals of surrounding soft tissue often mixed in postoperative MRI, which was difficult to distinguish. If the excision was performed according to postoperative MRI, the area was often too large, and the edematous normal soft tissue that wasn’t contaminated in the previous operation wound also be removed. This is unnecessary. Waiting for more than 3 months, the signal intensity of edema caused by operation wound gradually decreases, while the signal intensity of operative contamination or tumor does not decrease. At this time, MRI could be performed to evaluate the range area of excision, which could reduce unnecessary excision of soft tissue and reduce the area of soft tissue reconstruction. In our study, a total of 12 patients underwent MRI examinations at the time of postoperative visits and before re-excision. The mean maximum edema diameter was 93.8 mm and 54.9 mm, respectively. The latter area was significantly lower than the former one. In this aspect, delayed for more than 3 months operation is beneficial to the patients, and it reduce the area of excision and soft tissue reconstruction of patients. Finally, our study recommended that it is safe to wait for more than three months, which is strictly predicated on a rigorous ‘close monitoring’ protocol. In our clinical practice, this entails a highly structured follow-up regimen. Patients are typically evaluated with a baseline contrast-enhanced MRI at 3–4 weeks post-unplanned excision to map the initial extent of the hematoma and reactive edema. A subsequent MRI is performed at 10–12 weeks to assess the resolution of the edematous signal. During this waiting period, physical examinations are conducted every 4 weeks to monitor for rapid nodular growth, unexpected wound complications, or increasing pain, which would mandate an immediate shift from observation to early re-excision. The incorporation of advanced functional imaging, such as Diffusion-Weighted Imaging (DWI), may be recommended during this period to better differentiate organising seromas from true tumor recurrence. There were some limitations of this study. First, our study was a retrospective study, a non-prospective randomised controlled trial, and the level of evidence was relatively low. A subset of our cohort underwent delayed definitive surgery (≥ 3 months). This delay was not by design but was driven by several pragmatic clinical and logistical factors, inherently introducing selection bias. Late referral was a primary contributor, as many patients were initially observed or managed at primary care or non-specialized facilities before being transferred to our tertiary sarcoma center. Wound complications from the initial unplanned procedure, such as dehiscence or infection, often necessitated a prolonged period of local wound care and soft tissue optimization prior to a definitive wide resection. Diagnostic delays were frequent; the ambiguous histopathological nature of the initial specimens often required external expert pathology review, inherently prolonging the interval to secondary surgery. Moreover, patient-specific socioeconomic factors and personal preferences occasionally contributed to delays in seeking subsequent treatments. Therefore, the delayed re-excision group may represent a skewed subpopulation with more complicated initial wound beds or specific demographic profiles, which should be carefully considered when interpreting our oncological and functional outcomes. Second, it was a single-center study, and the number of patients in some subgroups is relatively small, resulting in some factors not showing significant differences in statistical analysis. Third, there were a few radiotherapy cases, and the corresponding analysis was not conducted in this study. Fourth, inherent selection bias exists regarding the allocation of patients to the immediate versus delayed re-excision groups. The decision to delay surgery was not randomised but was inevitably influenced by the clinical presentation at referral, such as the severity of postoperative edema, wound healing status, and the timing of consultation at our center. This introduces a potential confounding by indication. Fifth, while our radiological and operative data demonstrated a significant reduction in the extent of excision and the need for complex soft tissue reconstruction, our study lacks standardised, patient-reported functional outcome measures, such as the Musculoskeletal Tumor Society (MSTS) score or the Toronto Extremity Salvage Score (TESS). Consequently, the direct translation of a reduced surgical footprint into improved long-term functional recovery and quality of life remains to be prospectively validated. Finally, the pathological heterogeneity of our cohort is a recognised limitation. Soft tissue sarcomas encompass numerous histological subtypes with distinctly different biological behaviors and propensities for local invasion. Given the relatively small sample size, we were unable to perform robust subgroup analyses to determine if the safety of delayed re-excision varies among highly aggressive subtypes compared to indolent ones. Conclusions Delayed re-excision beyond three months does not adversely impact local recurrence, metastasis, or overall survival in STS patients. Under close clinical monitoring, this approach significantly reduces the requirement for complex soft tissue reconstruction, potentially improving functional outcomes.Whether the patient can wait for a longer time under close monitoring, or receive re-excision until local recurrence is unknown, and a prospective randomised controlled study is needed for analysis in future.